- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2014
- Public Summary Document (PSD) November 2014 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2014 PBAC Meeting - Word
Ranibizumab – November 2014
Ranibizumab; 2.3 mg/0.23 mL, 1 x 0.23 mL vial, 1.65 mg/0.165 mL, pre-filled syringe; Lucentis®
Last updated
6 March 2015